ABSTRACT
Zollinger-Ellison syndrome (ZES) results from an ectopic gastrin-secreting tumor leading to peptic ulcer disease, reflux, and chronic diarrhea. While early recognition portends an excellent prognosis with >80% survival at 15 years, symptoms are often nonspecific making the diagnosis difficult to establish. Diagnosis involves a series of tests, including fasting gastrin, gastric pH, chromogranin A, and secretin stimulation. Performing these tests in the correct sequence and at the proper time is essential to avoid inaccurate results. Tumor localization is equally nuanced. Although providers have classically used 111indium-radiolabeled octreotide with somatostatin receptor scintigraphy to evaluate tumor size and metastases, recent studies have shown superior results with newer imaging modalities. In particular, 68gallium (68Ga)-labeled somatostatin radiotracers (i.e., 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE) used with positron emission tomography/computed tomography can provide excellent results. Endoscopic ultrasound is another useful modality, particularly in patients with ZES in the setting of multiple endocrine neoplasia type 1. This review aims to provide clinicians with an overview of ZES with a focus on both clinical presentation and the proper utilization of the various biochemical and imaging tests available.
Subject(s)
Zollinger-Ellison Syndrome/diagnostic imaging , Zollinger-Ellison Syndrome/epidemiology , Abdominal Pain/blood , Abdominal Pain/diagnostic imaging , Abdominal Pain/epidemiology , Animals , Biomarkers/blood , Diagnosis, Differential , Gastroesophageal Reflux/blood , Gastroesophageal Reflux/diagnostic imaging , Gastroesophageal Reflux/epidemiology , Humans , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/epidemiology , Peptic Ulcer/blood , Peptic Ulcer/diagnostic imaging , Peptic Ulcer/epidemiology , Tomography, X-Ray Computed/methods , Zollinger-Ellison Syndrome/bloodABSTRACT
BACKGROUND: Zollinger-Ellison syndrome is a rare cause of tumoral hypergastrinemia; 1 of 5 patients with this syndrome also has multiple endocrine neoplasia type 1. The diagnosis of this disease is complicated by the widespread use of proton pump inhibitors that can elevate serum gastrin levels, the cornerstone for biochemical diagnosis. Abrupt discontinuation of proton pump inhibitors could lead to adverse outcomes. Clinician awareness of the relationship between Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1 could lead to a safer diagnostic pathway. METHODS: We conducted a retrospective review of a cohort of patients with multiple endocrine neoplasia type 1. RESULTS: There were 287 patients with multiple endocrine neoplasia type 1 (73 with gastrinoma) evaluated between 1997 and 2014. Two patients experienced adverse events after proton pump inhibitor therapy was discontinued to re-measure serum gastrin level during the evaluation of severe peptic ulcer disease. In both cases, the diagnosis of multiple endocrine neoplasia type 1 was made after proton pump therapy was discontinued. CONCLUSION: Abrupt discontinuation of proton pump therapy can lead to adverse outcomes in patients with Zollinger-Ellison syndrome. Clinical assessment for features of multiple endocrine neoplasia type 1 (eg, serum calcium levels, personal and family history of hypercalcemia, pituitary or pancreatic tumors) could identify patients with higher risk for a tumoral source of hypergastrinemia where imaging studies can help support the diagnosis without the potential side effects of abrupt discontinuation of proton pump inhibitor therapy.
Subject(s)
Multiple Endocrine Neoplasia Type 1/diagnosis , Zollinger-Ellison Syndrome/diagnosis , Adult , Duodenal Ulcer/drug therapy , Female , Gastrins/blood , Gastroesophageal Reflux/drug therapy , Humans , Male , Middle Aged , Proton Pump Inhibitors/therapeutic use , Retrospective Studies , Withholding Treatment , Zollinger-Ellison Syndrome/bloodABSTRACT
In the present paper the increasing difficulty of diagnosis of Zollinger-Ellison syndrome (ZES) due to issues raised in two recent papers is discussed. These issues involve the difficulty and need to withdraw patients suspected of ZES from treatment with Proton Pump Inhibitors (omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole) and the unreliability of many gastrin radioimmunoassays. The clinical context of each of these important issues is reviewed and the conclusions in these articles commented from the perspective of clinical management.
Subject(s)
Zollinger-Ellison Syndrome/diagnosis , Contraindications , Gastrins/blood , Humans , Proton Pump Inhibitors , Zollinger-Ellison Syndrome/bloodABSTRACT
BACKGROUND & AIMS: Zollinger-Ellison syndrome (ZES) is characterized by hypersecretion of gastric acid, severe peptic ulcerations in the upper small intestine, and diarrhea. It is usually diagnosed by measuring increased levels of gastrin in plasma. METHODS: We examined the accuracy of commercial kits to measure gastrin (7 radioimmunoassays and 5 enzyme-linked immunosorbent assays), using plasma from 40 patients suspected or known to have ZES. Each sample was analyzed using the 12 kits and a reference assay that measures bioactive gastrin in plasma, irrespective of size and amino acid derivatization. Known concentrations of peptides with identical sequences to circulating gastrins were also assessed by all assays. Molecular patterns in plasma from patients with ZES were examined by chromatography and monitored by kits that measure false-low or false-high concentrations of gastrin. RESULTS: Failure to diagnose gastrinomas has serious consequences. Four kits found false-low concentrations of gastrin in 20% to 80% of the patients. Specificity assessment showed that the antibodies used in these kits bound only gastrin-17. Three kits found false-high concentrations of gastrin, because the reagents had increased reactions to sulfated gastrins or to unspecific factors in plasma. Thus, only 5 of 12 kits tested accurately measure plasma concentrations of gastrin. CONCLUSIONS: Seven of 12 tested commercial kits inaccurately measure plasma concentrations of gastrin; these assays used antibodies with inappropriate specificity that were insufficiently validated. Misdiagnosis of gastrinoma based on lack of specificity of assays for gastrin results in ineffective or inappropriate therapy for patients with ZES.
Subject(s)
Gastrins/blood , Zollinger-Ellison Syndrome/blood , Adult , Aged , Diagnosis, Differential , Enzyme-Linked Immunosorbent Assay , False Positive Reactions , Female , Humans , Male , Middle Aged , Radioimmunoassay , Reproducibility of Results , Young Adult , Zollinger-Ellison Syndrome/diagnosisABSTRACT
BACKGROUND: Most patients with Zollinger-Ellison Syndrome (ZES), even those in whom gastrinoma is found and resected at initial operation, will suffer from persistent or recurrent disease in longterm followup. There is currently no consensus about managing patients with recurrent or persistent ZES. Our unit has historically maintained an aggressive approach toward monitoring and reoperation for patients with sporadic ZES. STUDY DESIGN: We performed a review of a consecutive series of patients evaluated and managed at our institution between 1970 and 2007 for ZES. "Biochemical cure" was defined as normal serum gastrin assays and negative imaging studies. Reoperations were performed for elevations in serum gastrin assays and positive findings on imaging studies. RESULTS: Fifty-two patients with sporadic ZES were analyzed. Median followup was 14 years. Among patients with sporadic ZES, 37 patients underwent operative management. The most common operations were resection of duodenal gastrinoma (n=8) and total gastrectomy (n=7). Nine patients underwent 15 reoperations for recurrent or persistent disease. "Biochemical cure" was obtained in four patients (44%) undergoing reoperation for ZES. Three of these patients remained without evidence of recurrence at 4, 9, and 12 years after their curative re-resection. Only one of nine patients who underwent reoperation died of metastatic gastrinoma. CONCLUSIONS: Primary and reoperative surgery in patients with sporadic ZES results in a significant rate of "biochemical cure." In selected patients with recurrent or persistent disease, reoperation for resection of gastrinoma is associated with excellent longterm survival and is warranted.
Subject(s)
Zollinger-Ellison Syndrome/surgery , Adolescent , Adult , Aged , Digestive System Surgical Procedures/statistics & numerical data , Duodenal Neoplasms/surgery , Female , Follow-Up Studies , Gastrectomy , Gastrinoma/surgery , Gastrins/blood , Hepatectomy/statistics & numerical data , Humans , Male , Middle Aged , Recurrence , Reoperation/statistics & numerical data , Retrospective Studies , Survival Analysis , Treatment Outcome , Young Adult , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/mortalityABSTRACT
The most frequent conditions of hypergastrinemia in man are the Zollinger-Ellison syndrome with autonomous gastrin hypersecretion by the tumour cell and reactive hypergastrinemia in type A autoimmune chronic atrophic gastritis with achlorhydria causing unrestrained gastrin release from the gastrin-producing antral G-cells. Both entities differ with respect to the pH in the gastric fluid, which is < 2 in patients with Zollinger-Ellison syndrome and neutral in type A gastritis. Other conditions with moderate hypergastrinemia as treatment with proton pump inhibitors, gastric outlet obstruction, previous vagotomy, chronic renal failure or short bowel syndrome are of minor clinical importance.
Subject(s)
Autoimmune Diseases/diagnosis , Duodenal Neoplasms/diagnosis , Gastrinoma/diagnosis , Gastrins/blood , Gastritis, Atrophic/diagnosis , Pancreatic Neoplasms/diagnosis , Stomach Neoplasms/diagnosis , Autoimmune Diseases/blood , Autoimmune Diseases/pathology , Carcinoid Tumor/diagnosis , Carcinoid Tumor/pathology , Diagnosis, Differential , Duodenal Neoplasms/blood , Duodenal Neoplasms/pathology , Enterochromaffin-like Cells/pathology , Gastric Mucosa/pathology , Gastrinoma/blood , Gastrinoma/pathology , Gastritis, Atrophic/blood , Gastritis, Atrophic/pathology , Humans , Hyperplasia , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/pathology , Stomach Neoplasms/blood , Stomach Neoplasms/pathology , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/diagnosis , Zollinger-Ellison Syndrome/pathologySubject(s)
Duodenal Neoplasms/diagnosis , Gastrinoma/diagnosis , Gastrins/blood , Neuroendocrine Tumors/diagnosis , Pancreatic Neoplasms/diagnosis , Zollinger-Ellison Syndrome/diagnosis , Autoimmune Diseases/blood , Autoimmune Diseases/diagnosis , Autoimmune Diseases/surgery , Diagnosis, Differential , Duodenal Neoplasms/blood , Duodenal Neoplasms/surgery , Early Diagnosis , Gastrinoma/blood , Gastrinoma/surgery , Gastritis, Atrophic/blood , Gastritis, Atrophic/diagnosis , Gastritis, Atrophic/surgery , Humans , Multiple Endocrine Neoplasia Type 1/blood , Multiple Endocrine Neoplasia Type 1/diagnosis , Multiple Endocrine Neoplasia Type 1/surgery , Neuroendocrine Tumors/blood , Neuroendocrine Tumors/surgery , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/surgery , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/surgeryABSTRACT
The Zollinger-Ellison syndrome is characterized pathophysiologically by a significant hypergastrinemia derived from a gastrin-secreting neuroendocrine tumor with a primary location in the pancreas or duodenum. Chronic hypergastrinemia in turn triggers gastric acid hypersecretion yielding in chronic or recurrent or refractory peptic ulcer disease and/or chronic diarrhea. One half of patients with ZES will have distant metastases in the liver by the time the diagnosis is established and one half of all patients with ZES will experience chronic diarrhea as chief complaint rather than peptic ulcer-related symptoms and signs. Gastrinomas have been reported to either manifest sporadically or to occur in conjunction with the genetic background of the MEN-I syndrome. Diagnosis is based on the patients history which is typically characterized by recurrent episodes of peptic ulcer disease or by severe reflux esophagitis and/or diarrhea or by acid-related symptoms which fail to respond to standard treatment regimens. Upper gastrointestinal tract endoscopy will provide evidence for peptic ulcer disease in anatomical regions located aborally the duodenal bulb within the descending part of the duodenum or even farther distally within the jejunum. Peptic ulcers frequently occur in groups indicating some substantial acid hypersecretion. A gastric pH > 2 is mutually exclusive for ZES. Increased serum gastrin levels confirm the diagnosis biochemically. Gastrin secretion can be determined in the basal state or following stimulation with secretin or calcium. High sensitivity and specificity for the diagnosis of ZES is provided by determining the ratio of basal versus pentagastrin-stimulated gastric acid secretion: The ratio of BAO / MAO > 0.6 is highly specific for gastrinoma. To localize the gastrin-secreting tumor computer-assisted tomography, endoscopic ultrasound, and somatostatin receptor scintigraphy provide useful help but most recently, endoscopic ultrasound with high resolution transducers appear to improve preoperative site localization. If modern imaging techniques fail to elucidate the site of the tumor, intraoperative diaphany may help to detect gastrinomas within the duodenal wall. Definitive treatment will only be achieved by total surgical resection of the gastrin-producing tumor in the pancreas or duodenum including dissection of the regional lymph nodes. Control of symptoms will have to be achieved by administration of highly potent proton pump inhibitors in up to 2-3-fold increased standard doses to inhibit gastric acid hypersecretion. Elevation of gastric pH > 4 will be the therapeutic target to protect the mucosa of the upper gastrointestinal tract. Basal acid output should be reduced to less than 10 mEq H(+) per hour which requires administration of highly potent proton pump inhibitors with a recommended starting dose of 60 mg omeprazole equivalents per day.
Subject(s)
Duodenal Neoplasms/diagnosis , Esophagitis, Peptic/drug therapy , Gastrinoma/diagnosis , Gastrins/blood , Pancreatic Neoplasms/diagnosis , Peptic Ulcer/drug therapy , Proton Pump Inhibitors/therapeutic use , Zollinger-Ellison Syndrome/diagnosis , Diagnosis, Differential , Duodenal Neoplasms/blood , Duodenal Neoplasms/drug therapy , Esophagitis, Peptic/etiology , Gastric Acidity Determination , Gastrinoma/blood , Gastrinoma/drug therapy , Humans , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/drug therapy , Peptic Ulcer/etiology , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/drug therapyABSTRACT
Cross sectional imaging in the assessment of gastrinomas has three major applications: Tumor localization (sporadic gastrinoma, MEN I) in patients undergoing primary or secondary surgery. Staging of metastasized tumors, especially assessment of lymph nodes and liver metastases, possibly including a risk analysis prior to liver resection. Post-surgery follow-up and monitoring of bio- or chemotherapy. Detection of primary tumors is strongly correlated with their size. However, the sensitivity of surgical assessment of the mostly small tumors by experienced surgeons is much higher than that of any imaging modality. Of all imaging modalities, endoultrasonography (EUS) followed by Somatostatin receptor scintigraphy (SRS) is the most sensitive modality for the assessment of pancreatic tumors in asymptomatic patients suffering from a MEN-I syndrome. Scintigraphy has the highest sensitivity in tumors of symptomatic patients and in the assessment of metastases. CT and MRI are only second line diagnostic modalities. Their sensitivity is largely dependent on the selection of patients. As a potential application, 3D reconstruction of nearly isotropic CT data sets for the risk assessment prior to liver resection is currently developing. Due to the absent radiation exposure, MRI is increasingly utilized to monitor the response of metastases under systemic therapy, e.g. in clinical trials.
Subject(s)
Duodenal Neoplasms/pathology , Gastrinoma/pathology , Gastrins/blood , Magnetic Resonance Imaging , Pancreatic Neoplasms/pathology , Tomography, X-Ray Computed , Angiography , Clinical Trials as Topic , Duodenal Neoplasms/blood , Duodenal Neoplasms/diagnosis , Duodenum/pathology , Gastrinoma/blood , Gastrinoma/diagnosis , Gastrinoma/secondary , Humans , Liver/pathology , Liver Neoplasms/blood , Liver Neoplasms/diagnosis , Liver Neoplasms/pathology , Liver Neoplasms/secondary , Lymphatic Metastasis/pathology , Multiple Endocrine Neoplasia Type 1/blood , Multiple Endocrine Neoplasia Type 1/diagnosis , Multiple Endocrine Neoplasia Type 1/pathology , Neoplasm Staging , Pancreas/pathology , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/diagnosis , Ultrasonography , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/diagnosis , Zollinger-Ellison Syndrome/pathologyABSTRACT
Gastrinoma is the most frequent functional pancreaticoduodenal endocrine tumor in patients with multiple endocrine neoplasia type 1 (MEN1) and one major determinant of mortality in this syndrome. Whether routine surgical exploration should be performed in a patient with MEN1 associated Zollinger-Ellison syndrome (ZES) to possibly reduce the malignant spread and eventually increase survival still remains controversial. There is not only disagreement about the indication for surgical exploration, but also what type of procedure should be performed, since sufficient evidence-based data are not available. The article discusses the available data on treatment strategies of MEN1 associated ZES.
Subject(s)
Duodenal Neoplasms/surgery , Gastrinoma/surgery , Gastrins/blood , Multiple Endocrine Neoplasia Type 1/surgery , Pancreatic Neoplasms/surgery , Disease Progression , Duodenal Neoplasms/blood , Duodenal Neoplasms/mortality , Gastrinoma/blood , Gastrinoma/mortality , Humans , Laparoscopy , Multiple Endocrine Neoplasia Type 1/blood , Multiple Endocrine Neoplasia Type 1/mortality , Pancreatectomy , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/mortality , Pancreaticoduodenectomy , Prognosis , Reoperation , Survival Rate , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/mortality , Zollinger-Ellison Syndrome/surgeryABSTRACT
Surgical therapy for sporadic gastrinoma profits from innovative pre- and intraoperative diagnostics. Preoperative gastrinoma localization is enhanced by sophisticated endoscopic ultrasonography, scintigraphic and arteriographic studies with hormone sampling. Thereby a concise surgical approach is guided and additional intraoperative control of success may be gained by endoscopic transillumination and measurement of stimulated gastrin levels.
Subject(s)
Duodenal Neoplasms/surgery , Gastrinoma/surgery , Gastrins/blood , Pancreatic Neoplasms/surgery , Diagnostic Imaging , Duodenal Neoplasms/blood , Duodenal Neoplasms/diagnosis , Gastrinoma/blood , Gastrinoma/diagnosis , Humans , Intraoperative Period , Neoplasms, Multiple Primary/blood , Neoplasms, Multiple Primary/diagnosis , Neoplasms, Multiple Primary/surgery , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/diagnosis , Prognosis , Transillumination , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/diagnosis , Zollinger-Ellison Syndrome/surgeryABSTRACT
Gastrinomas are functional neuroendocrine tumors of the gastroenteropancreatic system. Surgery is first line treatment in gastrinomas, however often fails to be curative. This manuscript reviews current strategies of medical treatment of surgically non-curable gastrinoma. Symptomatic treatment with H(+)-K(+)-ATPase proton-pump inhibitors suppresses hypersecretion of gastric acid and substantially improves quality of life in patients with Zollinger-Ellison syndrome. Further medical therapy is only recommended in cases of progressive metastatic gastrinoma. In well differentiated neuroendocrine carcinoma (G1 and G2) a so-called biotherapy with somatostatin analogues exists as first-line and chemotherapy with streptocotozin plus doxorubicine/5-FU as second-line medical treatment option. In poorly differentiated neuroendocrine carcinoma (G3) chemotherapy with etoposide plus cisplatin is possible. Prospective future therapeutic strategies may include treatment with novel somatostatin analogues as well as angiogenesis inhibitors and kinase inhibitors targeting tumor-specific signaling cascades.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Duodenal Neoplasms/drug therapy , Gastrinoma/drug therapy , Gastrins/blood , Pancreatic Neoplasms/drug therapy , Proton Pump Inhibitors/therapeutic use , Somatostatin/analogs & derivatives , Zollinger-Ellison Syndrome/drug therapy , Angiogenesis Inhibitors/therapeutic use , Clinical Trials as Topic , Duodenal Neoplasms/blood , Gastrinoma/blood , Humans , Interferon-alpha/therapeutic use , Octreotide/therapeutic use , Pancreatic Neoplasms/blood , Peptides, Cyclic/therapeutic use , Somatostatin/therapeutic use , Zollinger-Ellison Syndrome/bloodABSTRACT
PURPOSE: We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) cell hyperplasia, and in healthy participants (HPs). PATIENTS AND METHODS: Two hundred thirty-eight patients with NETs, 42 patients with CAG with or without ECL cell hyperplasia, and 48 HPs were studied. All patients underwent a baseline visit, biochemical routine check-up, imaging techniques, endoscopy, and histologic determination. RESULTS: CgA plasma levels were higher in patients with NETs compared with CAG patients or HPs (P < .001). In the NET group, we observed higher CgA levels in patients with diffuse disease compared with patients with local or hepatic disease (P < .001). CgA plasma levels were significantly higher in patients with Zollinger-Ellison syndrome compared with other types of endocrine tumors (P < .001). We found the best cutoff range between HPs and NET patients to be 18 to 19 U/L (sensitivity, 85.3%; specificity, 95.8%). Comparing all participants without neoplasia (HPs, CAG patients, and disease-free patients) and patients with endocrine tumors, the best cutoff range was 31 to 32 U/L (sensitivity, 75.3%; specificity, 84.2%). Setting the specificity at 95%, the cutoff range was 84 to 87 U/L (sensitivity, 55%). CONCLUSION: Our study confirms the high specificity and sensitivity of CgA in diagnosing an endocrine tumor. It is necessary to use a cutoff range of 84 to 87 U/L to obtain a high specificity in diagnosing NETs, with the aim of excluding patients in whom the CgA was elevated as a result of other non-neoplastic diseases.
Subject(s)
Biomarkers, Tumor/blood , Chromogranin A/blood , Enterochromaffin-like Cells/pathology , Gastritis, Atrophic/diagnosis , Neuroendocrine Tumors/diagnosis , Zollinger-Ellison Syndrome/diagnosis , Adult , Aged , Aged, 80 and over , Case-Control Studies , Diagnosis, Differential , Female , Gastritis, Atrophic/blood , Humans , Male , Middle Aged , Neuroendocrine Tumors/blood , Sensitivity and Specificity , Zollinger-Ellison Syndrome/bloodABSTRACT
The hormone gastrin plays 2 important roles in gastrointestinal physiology--1 as a major factor in meal-stimulated gastric acid secretion and the other as a trophic hormone for epithelial and enterochromaffin cells. These roles are exaggerated to the point of pathology under conditions of chronic hypergastrinemia as exemplified by the Zollinger-Ellison syndrome and pernicious anemia. More recently, the concern about the potential risk of chronic hypergastrinemia has risen because of the widespread use of proton pump inhibitors for maintenance therapy in reflux esophagitis. For this reason, we present a concise overview of the origin, causes, and potential risks of chronic hypergastrinemia.
Subject(s)
Enzyme Inhibitors/adverse effects , Gastrinoma/blood , Gastrins/blood , Gastritis, Atrophic/blood , Zollinger-Ellison Syndrome/blood , Animals , Gastric Acid/metabolism , Gastrins/drug effects , Humans , Peptic Ulcer/drug therapy , Peptic Ulcer/metabolism , Proton Pump Inhibitors , Risk FactorsABSTRACT
BACKGROUND: Zollinger Ellison syndrome (ZES), an ulcerative disease of the upper gastrointestinal tract that involves the production of high levels of gastrin and gastric acid, is a rare, symptomatic, endocrine neoplastic disease. CASE: We report a rare case of gastrinoma that was first diagnosed during pregnancy in which the primary tumor was located in the liver. The ZES was well controlled with Zoton (Lansoprazole) following surgery. The patient had an uneventful pregnancy and delivery without significant complications. CONCLUSIONS: The present case suggests that treatment with Zoton for ZES during pregnancy is safe and effective.
Subject(s)
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Anti-Ulcer Agents/therapeutic use , Gastrinoma/complications , Pregnancy Complications, Neoplastic/drug therapy , Zollinger-Ellison Syndrome/drug therapy , Adult , Female , Gastrinoma/drug therapy , Gastrinoma/pathology , Gastrinoma/surgery , Gastrins/blood , Humans , Infant, Newborn , Lansoprazole , Male , Pregnancy , Pregnancy Complications, Neoplastic/blood , Pregnancy Complications, Neoplastic/surgery , Pregnancy Outcome , Zollinger-Ellison Syndrome/blood , Zollinger-Ellison Syndrome/complications , Zollinger-Ellison Syndrome/surgeryABSTRACT
In two-thirds of patients with Zollinger-Ellison syndrome (ZES), fasting serum gastrin (FSG) levels overlap with values seen in other conditions. In these patients, gastrin provocative tests are needed to establish the diagnosis of ZES. Whereas numerous gastrin provocative tests have been proposed, only the secretin, calcium, and meal tests are widely used today. Many studies have analyzed gastrin provocative test results in ZES, but they are limited by small patient numbers and methodologic differences. To address this issue, we report the results of a prospective National Institutes of Health (NIH) study of gastrin provocative tests in 293 patients with ZES and compare these data with those from 537 ZES and 462 non-ZES patients from the literature. In 97%-99% of gastrinoma patients, an increase in serum gastrin post secretin (Delta secretin) or post calcium (Delta calcium) occurred. In NIH ZES patients with <10-fold increase in FSG, the sensitivity/specificity of the widely used criteria were as follows: Delta secretin > or =200 pg/mL (83%/100%), Delta secretin >50% (86%/93%), Delta calcium > or =395 pg/mL (54%/100%), and Delta calcium >50% (78%/83%). A systematic analysis of the sensitivity and specificity of other possible criteria for a positive secretin or calcium test allowed us to identify a new criterion for secretin testing (Delta > or =120 pg/mL) with the highest sensitivity/specificity (94%/100%) and to confirm the commonly used criterion for calcium tests (Delta > or =395 pg/mL) (62%/100%). This analysis further showed that the secretin test was more sensitive than the calcium test (94% vs. 62%). Our results suggest that secretin stimulation should be used as the first-line provocative test because of its greater sensitivity and simplicity and lack of side effects. In ZES patients with a negative secretin test, 38%-50% have a positive calcium test. Therefore the calcium test should be considered in patients with a strong clinical suspicion of ZES but a negative secretin test. Furthermore, we found that some clinical (diarrhea, duration of medical treatment), laboratory (basal acid output), and tumoral (size, extent) characteristics correlate with the serum gastrin increase post secretin and post calcium. However, using the proposed criteria, the result of these provocative tests (that is, positive or negative) is minimally influenced by these factors, so secretin and calcium provocative tests are reliable in patients with different clinical, laboratory, and tumor characteristics. A systematic analysis of meal testing showed that 54%-77% of ZES patients have a <50% postprandial serum gastrin increase. However, 9%-20% of ZES patients had a >100% increase post meal, causing significant overlap with antral syndromes. Furthermore, we could not confirm the usefulness of meal tests for localization of duodenal gastrinomas. We conclude that the secretin test is a crucial element in the diagnosis of most ZES patients, the calcium test may be useful in selected patients, but the meal test is not helpful in the management of ZES. For secretin testing, the criterion with the highest sensitivity and specificity is an increase of > or =120 pg/mL, which should replace other criteria commonly used today.
Subject(s)
Calcium/blood , Eating/physiology , Gastrins/blood , Secretin/blood , Zollinger-Ellison Syndrome/diagnosis , Female , Humans , Male , Middle Aged , Multiple Endocrine Neoplasia Type 1/blood , Multiple Endocrine Neoplasia Type 1/diagnosis , Multivariate Analysis , Prospective Studies , Sensitivity and Specificity , Zollinger-Ellison Syndrome/bloodABSTRACT
Many gastric acid hypersecretory states (basal acid output of greater than 15.0 mEq/h) exist for which the etiology is known, such as Zollinger-Ellison syndrome, systemic mastocytosis, antral exclusion, antral predominant Helicobacter pylori gastritis (antral G cell hyperplasia), chronic gastric outlet obstruction, short gut syndrome and basophilic leukemias. However, many hypersecretory patients have no identified etiology for their acid hypersecretion and are designated as idiopathic gastric acid hypersecretors with a basal acid output of greater than 10 mEq/h and a normal serum gastrin level. Because of the gastric acid hypersecretion these patients also commonly have an increased frequency of stools. Idiopathic gastric acid hypersecretion represents a known cause of gastric acid hypersecretion that is far more common than Zollinger-Ellison syndrome and it has a markedly different treatment regimen and natural history. We report a case of a patient with idiopathic gastric acid hypersecretion previously misdiagnosed as having Crohn's disease because of a presenting complaint of diarrhea and mimicking Zollinger-Ellison syndrome because her fasting serum gastrin level was elevated when incorrectly measured in the presence of antisecretory treatment.